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Abstract
Purpose of Review Whole exome sequencing (WES) and whole-genome sequencing (WGS) are frontline approaches for the
genetic diagnosis of rare diseases. However, WES/WGS fails in up to 75% of cases. Transcriptomics via RNA-sequencing
(RNA-Seq) is a novel approach that aims to increase the diagnostic yield in rare diseases.
Recent Findings Recent publications focus on the success of RNA-Seq for increasing diagnosis rates in WES/WGS-negative
patients in up to 36% of cases, across a range of different diseases, sample sizes, and tissue types.
Summary RNA-Seq is beneficial for aiding prioritisation of causative variants currently not detected or often overlooked by
WES/WGS alone. An improvement in diagnostic yields has been demonstrated using multiple source tissues, with muscle and
fibroblasts being the most representative, but the more accessible blood still demonstrating diagnostic success, particularly in
neuromuscular disorders. The introduction of RNA-Seq to the genetic diagnosis toolbox promises to be a useful complementary
tool to WES/WGS for improving genetic diagnosis in patients with rare disease.
Keywords RNA-sequencing . Rare disease . Transcriptomics . Next-generation sequencing (NGS) . Whole exome sequencing
(WES)
Introduction
Rare diseases affect over 350 million individuals worldwide,
with ~8% of live births having a Mendelian genetic disorder
recognisable by early adulthood [1, 2]. Accurate identification
of causal variants in rare diseases is imperative, not only pro-
viding the patient with a genetic diagnosis and ending years of
diagnostic odyssey but also permitting more accurate
prognosis, improving family risk planning, and enabling re-
search for novel therapeutic interventions. Improvement of
genetic sequencing techniques, from Sanger sequencing
through to next-generation sequencing (NGS), has seen a vast
expansion in the ability to identify variation in individuals.
This review briefly describes the history of causal variant
identification, before exploring the advantages and disadvan-
tages of using RNA-sequencing (RNA-Seq) as a pioneering
method in the genetic diagnosis of a variety of rare diseases.
We emphasise its success in improving diagnostic yields,
across an array of tissue sources and cohort sizes, when used
independently and as part of a larger multi-omics approach.
Next-Generation Sequencing (NGS)
Next-Generation Sequencing (NGS) is used in various appli-
cations such as examining DNA sequences (whole-genome
sequencing (WGS), whole-exome sequencing (WES)), inves-
tigating DNA and histone modifications (ChIP-Seq, Methyl-
Seq, ATAC-Seq), and RNA-Sequencing, with the commercial
sequencing technologies currently being dominated by
Illumina [3]. WGS allows sequencing of the genome with near
complete coverage, and typically will identify ~3 million
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single nucleotide variants (SNVs) [4, 5]. WES focuses only on
the protein-coding region of DNA, which constitutes ~2% of
the genome, and reduces the average number of SNVs to
23,000 [4, 5].
WES is currently a first-tier approach for genetic diagnosis
of Mendelian disorders, due to the vast majority of disease
variants reported being located in coding regions. Improved
diagnostic yields have prompted decreased healthcare costs
and improvement in patients’ quality and outcomes [6, 7].
However, despite an improvement in bioinformatic ap-
proaches, the diagnostic yield remains low and variable, at only
25–50%, leaving a large proportion of individuals awaiting a
genetic diagnosis [4]. The limitations of WES include the ever-
emerging challenge of interpreting variants of unknown signif-
icance (VUS), including variants in genes not yet associated to
any disease, and the limited efficacy of WES to identify struc-
tural rearrangements, copy number variants and tandem repeat
expansions, as well as G-C andA-T rich regions of the genome.
Furthermore, despite previously being overlooked due to re-
search bias and their exclusion through use of stringent filtering
techniques, synonymous, intronic, and noncoding variants
could also be pathogenic. Evidence suggests that 9–30% of
disease-causing variants are in non-coding regions and that
there are synonymous variants associated with over 50 different
diseases [8]. This demonstrates the increased importance of
scrutinising these overlooked variant classes.
As NGS gets cheaper and more available to diagnostic labs,
the far more comprehensive technique of WGS will rise in
prominence as it does sequence non-coding regions. However,
the sheer amount of data poses the large bioinformatic challenge
of interpreting 3 million SNVs per sample, followed by the
additional functional validation. One particular type of variant
that causes bioinformatic difficulties with current approaches is
splicing variants. These are reported to account for up to 10% of
disease causing variants, a figure speculated to be
underestimated [9]. Consequences of these mutations can lead
to exon creation, skipping, truncation, extension, and intron re-
tention [10]. These pose analytical challenges when investigat-
ing WES and WGS data. Although canonical splice mutations
can be identified using these techniques, both cryptic and en-
hancer sites still provide interpretation challenges.Moreover, the
vast majority of intronic variants are not identified at all by
WES, whilst they are too abundant to prioritise fromWGS data
andmost often remain as VUSs. Thus, there is amass shift in the
challenges faced by clinicians and scientists today, away from
being able to sequence genomes comprehensively and more
towards interpreting the large datasets generated by them and
translating this information into actionable results. Additionally,
the high number of VUSs identified highlights the importance of
re-filtering NGS data as new disease genes emerge. Recently,
RNA-sequencing-based transcriptomics is starting to become a
major player in genetic diagnostics for aiding annotation and
interpretation of these types of variants.
RNA-Sequencing
Since the discovery of reverse transcriptases and their use to
create cDNA in 1971, followed by the ability tomeasure RNA
on a singular gene basis using RT-PCR in 1990, analysis of
RNA has been available to observe the effect of pathogenic
variants [11, 12]. RNA-Seq allows the entire transcriptome
(~12,800 transcripts) to be analysed in a single run [13].
Initially, this technology was clinically applied for determina-
tion of viral gene expression, monitoring of immune re-
sponses, or for the most part, in cancer diagnostics to readily
detect gene fusions [14–17]. More recently, RNA-Seq has
been used successfully to genetically diagnose those with
Mendelian disorders as the primary method or as part of a
larger multi-omics approach. Whereas RT-PCR has been pre-
viously utilised for its abilities to confirm candidate variants,
the ever-reducing costs of RNA-Seq make it an equally viable
option not only for validation purposes but also in providing
additional transcriptome annotation [5, 18].
Briefly, the protocol used for RNA-Seq is total RNA iso-
lation and purification and library preparation; enrichment for
RNA of interest, e.g. filtered for poly(A) tails to capture
mRNA and reverse transcription to cDNA; fragmentation of
sample, addition of adaptors and barcodes/indexes; and am-
plification. Next automatic sequencing occurs, followed by
reassembly of transcriptomic data, where the results are
bioinformatically analysed (Fig. 1) [19]. There are numerous
tools available to fully analyse the data, though comparison of
RNA data with that of a comprehensive control dataset, such
as data provided by the GTEx consortium atlas of genetic
regulatory effects across human tissues (GTEx), is recom-
mended. GTEx is an ongoing effort towards building a public
resource for scientists to use, which is comprised of data from
54 human tissues from approximately 1000 donors [20].
Alternatively, independent study control data sets have also
been utilised instead of GTEx in multiple studies of varying
cohort sizes [4, 21]. RNA-Seq technology enables detection of
transcriptome defects, a functional consequence of deleterious
variants that usually cannot be predicted from the WES/WGS
data alone. As underlined in a previous review by Kremer
et al. [5], it enables the identification of aberrant gene expres-
sion levels between control and experimental samples, reveals
allele-specific expression, and provides information on aber-
rant splicing events (vide infra).
Studies Utilising RNA-Seq in Genetic
Diagnostics
The quantity of papers that have started utilising
transcriptomic techniques to improve diagnostic levels in
WES/WGS-negative patients has increased over the past few
years (Table 1). Primary articles of note on this subject include
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Cummings et al. [22] who yielded a genetic diagnosis in 35%
of their cohort of patients with previously undiagnosedmuscle
disorders; Kremer et al. [4] attained a genetic resolution of
10% in their cohort of patients with diverse phenotypes of
mitochondrial disease; Kernohan et al. [21] explored the po-
tential use of whole blood for RNA-Seq in a single patient; as
well as Gonorazky et al. [23] who described a 36% genetic
diagnosis in their cohort of patients with previously undiag-
nosed neuromuscular disorders. Furthermore, even more re-
cent papers include Frésard et al. [24], who reported a 7.5%
diagnostic rate utilizing multiple source tissues for a diverse
range of diseases, and Maddirevula et al. [25] who support the
use of blood as a source of RNA material in neurological
disorders. In contrast, Rentas et al. [26] explore the option of
using B-lymphoblastoid cell lines (LCL) from patients to an-
alyse expression and splicing. Additionally, Lee et al. [27]
find an 18% diagnostic yield in a heterogenous cohort,
while Murdock et al. [28] suggest a novel method of inte-
grating RNA-Seq data that contrasts the commonly used
candidate gene approach used in most studies. Instead,
Murdock et al. suggest starting with RNA-Seq and, thus
excitingly, advocate its role in research and gene discovery.
These papers will be further discussed in order to demon-
strate the success of RNA-Seq thus far, specifically in ab-
errant expression levels, splicing events and allele specific
expression, as well as to highlight difficulties still present in
this continually developing approach and discuss its place
in both the diagnostic and research setting.
Aberrant Gene Expression Levels
Aberrant gene expression levels can be described as a gene
expression level outside its normal physiological range. This
process is tightly regulated by chromatin packing, histone
modification, transcription initiation, RNA polyadenylation,
splicing, and translation initiation, with both exonic and
intronic variants disrupting these functions. Approximately
1% of disease-causing variants are estimated to be located
within promoter regions, thus disrupting gene activation and
transcriptional initiation [29]. Furthermore, splicing mutations
can also lead to changes in gene expression and will be
discussed within the context of the limitation of WES and
WGS in further detail (vide infra).
Success of utilising RNA-Seq to investigate gene expres-
sion has been reported with an additional diagnostic yield of
10% by Kremer et al. [4]. In particular, RNA-Seq enabled
identification of reduced expression of a nuclear encoded mi-
tochondrial protein (MGST1 and TIMMDC1) in three patients
(MGST1 (n = 1) and TIMMDC1 (n = 2) from a
mitochondriopathy cohort (n = 48). Here, quantitative prote-
omics validated severe loss-of-function in these patients.
Interestingly, this included a deeply intronic variant in
TIMMDC1, which could never be identified in WES whilst
overlooked in WGS, but RNA-Seq helped identify it as a
novel disease–associated gene with mitochondrial disease.
This emphasises the use of RNA-Seq not only in genetic di-
agnosis but also in gene discovery, as well as the importance
of intronic variants in disease.
Frésard et al. [24] highlights the need for stringent filtering
criteria when investigating gene expression, with 343 expres-
sion outliers averaged per sample (n = 94). Following the
prioritisation of the Human Phenotype Ontology (HPO)
matching genes, containing deleterious (CADD ≥ 10), rare
(minor allele frequency (MAF) ≤ 0.1%) variants within 20
bp, ~1% of identified outliers remained, with at least 80% of
samples having at least one candidate gene remaining. Novel
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Fig. 1 RNA-sequencing protocol. RNA-sequencing offers the
opportunity to add additional variant annotation to individuals who
have previously undergone other forms of genetic testing either
unsuccessfully or resulting in variants of unknown significance (VUS).
Additionally, it can be used as a completely independent diagnosis
technique for novel patients. RNA-Seq protocol steps include the
isolation of RNA from chosen tissue; library preparation; sequencing;
reassembly of transcriptomic data; and bioinformatic analysis of results.
Resources often utilised during sequencing include PAGE [23], MAJIQ-
CAT [43], Illumina [45], STAR [46], HISAT [47], PICARD [48],
RNASeQC [49], EdgeR [50], OUTRIDER [31], and FRASER [40].
Data achievable from RNA-Seq encompasses gene expression, aberrant
splicing, and mono-allelic expression
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genetic causeswere discovered in four patients following gene
expression analysis, including two brothers experiencing de-
layed milestones and hypotonia for whom a large number of
variants remained followingWGS analysis (n = 245 and 302).
The addition of expression data substantially reduced the
number of candidate variants (n = 11 and 15), including a
heterozygous pathogenic variant in MECR in both siblings.
This provided a MEPAN disorder diagnosis for both patients
[30] and demonstrated the advantage of combining RNA-Seq
with WGS to answer the challenges of variant prioritisation.
Murdock et al. [28] support the idea of using a multi-omics
approach rather than solelyWGS orWES for intronic variants
after a deeply intronic variant was observed in a 3-yr-old male
patient with multiple congenital abnormalities. Here, a 50%
reduction in the expression of PQBP1 from whole blood was
associated to a hemizygous variant in PQBP1, resulting in an
activated cryptic splice donor, abnormal splicing pattern and
intron retention. This had been previously overlooked by
WES and WGS due to the poor reliability of bioinformatic
in silico prediction tools concerning splice-site mutations.
Identification of this maternally inherited hemizygous variant
resulted in a diagnosis of Renpenning syndrome. This discov-
ery allowed recurrent risk discussions within the family,
highlighting the importance of an accurate genetic diagnosis.
Furthermore, Gonorazky et al. [23] developed PAGE
(Panel Analysis of Gene Expression), a webtool which en-
ables visualisation of expression levels across multiple tissues.
Even more interestingly, it identifies the best tissues to study
when performing RNA-Seq, as “disease” tissue is not always
easily attainable. Excitingly, statistical methods such as
OUTRIDER have also been recently developed to further
aid the identification of abnormal gene expression [31].
Altogether, this emphasises the increasing usefulness of
RNA-Seq in genetic diagnosis. Whilst WES data analysis
could potentially identify a synonymous VUS, it would most
likely have been excluded during variant prioritisation, where-
as an intronic variant would likely not even be sequenced.
Thus, quantifying global RNA expression by RNA-Seq has
proved to be invaluable in interpreting VUSs for genetic
diagnosis.
Aberrant Splicing
Splicing is estimated to occur in ~94% of human genes, with
alternative splicing occurring in the vast majority of these
[32]. Both intronic and exonic variants can affect splice sites,
or cis-regulatory sites, and can therefore have drastic conse-
quences and lead to aberrant splicing. These include exon
skipping, exon extension, exon truncation or deletion, intron
retention, pseudoexon creation and alteration in isoform abun-
dance [10]. The effects of these variants can range in severity
and can trigger loss of function or nonsense-mediated decay
and affect gene expression, and therefore accurate evaluation
of these mutations is vital.
As mentioned above, splice variants are not only highly
detrimental, accounting for at least 15% and potentially up
to 60% of genetic diseases [33, 34], but also are located in
both exons and introns. An obvious limitation of WES for
identifying individuals with these types of variants is that
splice-modifying variants that lie beyond the exome are not
captured. Furthermore, it is commonly seen that splicing var-
iants lying within the sequencing range are still often
overlooked, thus highlighting downfalls of current
prioritisation protocols, which also extends to WGS tech-
niques. Kernohan et al. [21] emphasise that despite the devel-
opment of many in silico prediction tools over the last 20 years
to help prioritise potentially pathogenic variants (including
MaxEntScan [35], GeneSplicer [36] , SPANR [37] and
VEP [38]), many are still overlooked. Equally, due to an
underappreciation and the undereducation of the impact of
splicing variants, particularly synonymous variants and variants
lying outside of the coding regions, prediction tools are report-
ed to overlook splicing events and provide incorrect predictions
up to 76.1% of the time [39]. Lee et al. [27] support this sug-
gestion, reporting only 4.3% of predicted damaging splice var-
iants actually resulting in an impact after RNA-Seq validation.
This is an area in need of improvement in order for splicing
prediction to become accurate and routine using WES or WGS
and suggests an underestimation of their potentially pivotal role
in identification providing genetic diagnosis. RNA-Seq, how-
ever, aids the annotation of these synonymous variants or
VUSs in order to validate disease involvement. Additionally,
the recent development of the FRASER algorithm holds prom-
ise for effective identification of these variants [40].
The advantages of RNA-Seq were noted by Kremer et al.
[4] who demonstrated that although candidate splicing vari-
ants were often sequenced in WGS and WES, few were being
validated due to lack of appropriate assays and biomaterials.
This therefore emphasises the importance of combining tradi-
tional NGS techniques with RNA-Seq in both diagnostic and
research settings to tackle the increasing problem of VUS
interpretation and identifying true damaging variants. With
five aberrant splice sites identified on average in their cohort
of neuromuscular and inborn errors of metabolism (IBM) pa-
tients, exon skipping and new exon formation were identified
as the most common types of splicing mutations. The impor-
tance of quantitative proteomics and validation of any identi-
fied variants via western blotting was also emphasised.
Cummings et al. [22] created a splicing prediction algorithm
in 50WES/WGS-negative muscle disorder patients, detecting
abnormal exon junctions and abnormal splicing events in up
to 190 genes per individual, compared to GTEx control data.
This included synonymous variants in both RYR1 (n = 1) and
POMGNT1 (n = 1) that were discovered to influence aberrant
splicing in patients. Furthermore, they identified deep intronic
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variants in DMD that led to pseudoexon construction and
early stop codon creation in three patients. For both types of
variants their contribution would have been typically
overlooked amongst the mass of WGS variants prioritized
and even undetected using current frontline WES diagnostic
techniques.
Kernohan et al. [21] tackled the largest difficulty that
arises with application of using RNA-Seq—tissue avail-
ability. In contrast to Cummings et al. [22], the availabil-
ity and non-invasive nature of collecting RNA from
whole blood are widely appreciated. Kernohan et al.
[21] demonstrate the capability of using RNA-Seq on
blood leukocytes to identify the underlying pathogenic
variant in a single patient. Here, they detected a previous-
ly unidentified splice mutation in ASAH1, resulting in an
autosomal recessive spinal muscular atrophy diagnosis.
This indicates the value of transcriptomics even in smaller
cohorts or even individual patients.
Frésard et al. [24] and Lee et al. [28] expand this work
further by conducting RNA splicing studies on larger heter-
ogenous disease cohorts (n = 94 and n = 100, respectively),
containing adult and paediatric patients, on whole blood
as well as other tissues, including muscle and fibroblast
cells. Both studies reported increased diagnostic rates (7.5
and 18%, respectively) across a range of disorders, with
Frésard et al. [24] stressing the feasibility of using blood
in patients where biopsy is not routine. Variants identified
were both intronic and exonic mutations that triggered a
wide range of splicing events, despite previously being
completely missed or overlooked VUSs during WES and
WGS. Of note again, neuromuscular and musculoskeletal
patients were amongst the highest proportion of patients
in these studies, suggesting a bias of success for these
types of rare disease patients.
Strict filtering criteria (HPO relevant genes with a del-
eterious variant (CADD ≥ 10) within 20 bp of a splice
junction) enabled Frésard et al. [24] to achieve a reduction
of candidate variants to 0.14%, with 32% of individuals
still remaining with at least one gene candidate. It was
commented that such stringent filtering will still lead to
a loss of some potentially pathogenic variants; thus expert
analysis is still vital to conduct RNA-Seq analysis effec-
tively. Throughout the studies, GTEx data was commonly
used as control data. Frésard et al. [24] also emphasise the
importance of accounting for batch effects in large control
cohorts, such as GTEx, as well as matching controls for
tissue and sex, in order to show the largest difference in
RNA data and identify variants. Overall, the in silico pre-
diction tools available have been seen to be inconsistent
in the prediction of splicing variants. RNA-Seq offers an
opportunity to correctly identify both intronic and exonic
variants leading to varied splicing events across a range of
diseases and tissues.
Allele-Specific Expression or Mono-Allelic
Expression (MAE)
Mono-allelic expression (MAE) refers to the incidence where
imbalanced expression of alleles occurs, or only one of a pa-
tients two alleles is being expressed. The silencing of one
allele may occur due to deletions or variants that cause genetic
or epigenetic changes. This is a phenomenon that can occur
normally withwell-known examples including immunoglobulin
gene exclusion, X-inactivation, and genomic imprinting [41].
However, abnormal allele expression or allelic imbalance can
result in a clear disease phenotype, such as Prader-Willi syn-
drome [42]. In these scenarios, the investigation of unbalanced
allelic expression is an area of interest in genetic diagnosis that
RNA-Seq can shed light on, by aiding variant annotation.
During the filtering and prioritisation of compound het-
erozygous variants following WES or WGS, a recessive
form of inheritance is assumed; thus single heterozygous
rare coding variants are often dismissed. However,
Kremer et al. [4] suggest how these variants when solely
expressed due to allelic silencing mimic homozygous var-
iants with similar and identifiable effects at RNA level.
They prioritised rare SNVs (minor allele frequency
(MAF) < 0.001) and high coverage (> 10)) following
RNA-Seq that were mono-allelically expressed in more
than 80% of these reads (p < 0.05). This resulted in an
average of 6 MAE events per sample, a number noted to
be small enough for manual inspection, in contrast to
WGS. Here, aberrant expression and MAE reprioritized
an ALDH18A1 variant in a WES-negative patient, after
it was identified in a compound heterozygous state with
a previously annotated VUS nonsense variant. Proteomic
validation of the variant supported pathogenicity.
Frésard et al. [24] proposed a higher rate of MAE per sam-
ple (n = 94) vs. GTEX controls. Following filtering of rare and
deleterious variants in their heterogenous cohort (n = 94), 111
variants demonstrated allelic imbalance towards the mutated
allele, including 96 splice variants and 15 stop-gain mutations.
In particular, a EFDH2 variant, involved in B-cell apoptosis
and inflammatory response, led to the genetic diagnosis of a
previously undiagnosed individual with idiopathic cardiomy-
opathy. This example highlights the potential of using RNA-
Seq in combination with other NGS techniques to identify
variants or even reprioritize variants previously discarded
due to lack of annotation available.
Limitations of RNA-Seq
Tissue Specificity
Despite recent publications succeeding in providing an in-
creased diagnostic rate of 7.5–36%, limitations to RNA-Seq
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still remain. The most prominent challenge is finding the ap-
propriate balance of tissue specificity of gene expression vs.
accessibility and invasiveness of tissue collection. Some larger
studies have focused on mitochondrial and neuromuscular
diseases, where muscle biopsies and fibroblast collection are
routine as part of disease management. The benefit of using
fibroblasts in mitochondrial disorders was supported by
Kremer et al. [4] highlighting that 68% of disease genes report-
ed in OMIM are expressed in fibroblasts and with many recent
papers still arguing the ineffectiveness of blood for being rep-
resentative in many conditions, despite it being easily accessi-
ble and feasible [23, 27, 28]. In this regard, Murdock et al. [28]
reported that half of the pathogenic splice variants identified did
not have an observable functional consequence following
RNA-Seq in blood, whereas all had a functional consequence
in fibroblasts. Furthermore, principal component analysis
(PCA) studies reveal that fibroblasts have genes with compar-
atively better expression levels (Transcript Per Million (TPM)
> 10) vs. blood, most prominently in aorta cardiomyopathy
genes (80% vs. 24%) and with the only anomaly being immu-
nodeficiency genes (45% vs. 58%). In contrast, Frésard et al.
[24] reports 70.6% of OMIMgenes to be expressed in blood, as
well as 76% of neurological disease panel genes (n = 284)
being well expressed in blood. Furthermore, they go on to
suggest the appropriateness of blood, as causative loss of func-
tion (LOF) and missense mutations were seen at higher levels
in genes that are expressed in multiple tissues with 66% of
genes that are most intolerant to LOF mutations (pLI < 0.9)
being expressed in blood. Interestingly, Maddirevula et al. [25]
and Kernohan et al. [21] support the use of blood, with
Kernohan et al. [21] showing that 71% of motor neuron panel
genes were seen expressed in the blood of at least half of their
cohort. Musculoskeletal and neuromuscular diseases are
still frequently those seen to be successfully aided from
RNA-Seq experiments, with appropriate tissues available.
Rentas et al. [26] highlight the use of LCL over blood,
demonstrating 90% in sensitivity using their pipeline
which utilises splicing and expression data, with a reported
1.8 fold higher expression of neurodevelopmental genes in
LCL than in blood, in their cohort (n = 5). Nevertheless,
many studies have pinpointed neurologically pathogenic
variants in blood and other tissues, despite their non-
haematological phenotypes [24]. The recently developed
MAJIQ-CAT resource offers the opportunity to identify
clinically accessible tissues offering the best representa-
tion of splicing events in the gene or tissue of interest
[43]. Overall, the discussion about the best tissue to use
for RNA-Seq is ongoing, with the general consensus being
that if the affected tissue is easily accessible, then it should
be prioritized for use in RNA-Seq. However, when not
available, whole blood or other GTEx identified “proxy”
tissues have still been seen to effectively diagnose individ-
uals with a variety of pathologies.
Potential emerging techniques could begin to tackle the
tissue specificity problem where disease-relevant tissue is
unattainable. One option is the non-trivial procedure of re-
programming patient cells of different tissue types into
“disease” cells. Yamanaka’s factors can induce specific
forced gene expression from easily accessible tissues from
the patient, resulting in induced pluripotent stem cell
(iPSC) formation that can then be differentiated into the
desired and patient-specific disease tissue type [44].
Alternatively, a more recent advancement using trans-
differentiation techniques may be used to produce
patient-specific cells in a faster and more efficient manner
[23]. Another aspect to consider is that RNA-Seq typical-
ly relies on the incorrect assumption that all cells within
the same tissue are relatively homogeneous, an exciting
potential solution here being single-cell RNA-Sequencing
(scRNA-Seq).
Database Biases
The variability of gene expression throughout a person’s
lifespan is another consideration for RNA-Seq. Despite the
vast resources already available, there is still a need for more
comprehensive gene expression datasets encompassing a
range of ages. GTEx donor information describes that the
majority are aged between 50 and 70 years (64.7%), causing
potential difficulties in paediatric cases [20]. Further database
biases are noted including gender and race whereby 67.1% of
data is provided frommale donors, and the racial input of data
is predominantly white (84.6%) [20]. Increased variation in
database recruitment, alongside control matching could fur-
ther increase diagnostic yields.
Validation of Transcriptomic Data
Finally, RNA-Seq will provide information on gene expres-
sion, allele-specific expression, and splicing events; however,
gene expression is not always a good proxy for protein abun-
dance. Following transcription, regulation at or prior to the
translational level is also present, e.g. nonsense-mediated decay
(NMD). Therefore, validating the impact of RNA splicing var-
iants at the level of the protein is good practice.
Conclusion
In conclusion, despite the exponential growth and develop-
ment of NGS techniques, at least 50% of individuals investi-
gated with WES or WGS for a genetic diagnosis remain un-
diagnosed, thereby hindering disease management at many
levels. Reasons include sequencing bias of WES, alongside
poor in silico prediction tools and filtering, and the vast num-
ber of VUSs produced inWGS. Recent publications highlight
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the success of employing transcriptomic data provided by
RNA-Seq to improve diagnostic yields in a wide range of rare
diseases, using both fibroblasts and muscle tissue, with mus-
cular and neurological conditions reporting the most success.
Publications demonstrate the significance of conducting RNA
sequencing in both individual undiagnosed cases and larger
cohorts, particularly in highlighting previously underappreci-
ated non-coding and synonymous variants. Tissue specificity
remains an issue, though even whole blood has been seen to
successfully increase diagnostic rates. This suggests that effi-
cient protocols for the use of RNA-Seq in both diagnostic and
research settings are established. It should however be ac-
knowledged that variants will still be overlooked, even when
applying RNA-Seq, namely, if they are not detectable by
short-read sequencing such as RNA-Seq, filters applied to
the transcriptomic data are too stringent, or if the causative
variant does not affect expression. Overall, reported studies
emphasise the versatility and practicality of using RNA-Seq as
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